Hepatitis C: A Silent Killer

This research paper is going to review today’s silent killer, the Hepatitis C virus. This paper will talk about the description of the disease, the signs and symptoms, the etiology and risk factors, diagnostic studies, treatments and prognosis of this disease. I had lived with this disease for over ten years before diagnosed so it is important to understand the signs and symptoms so the disease can be identified and a treatment plan can be identified as the sooner it is treated the more likely it will eradicate the disease.

Hepatitis C virus (HCV) is from the virus family Flaviviridae with an RNA envelope serving as it's genetic material. The genetic material (RNA) is HCV's pathogenic structure. The genome is positive sense single stranded RNA, which is very similar to mRNA and can be translated quickly to the host cell (Bauman 2012). Hepatitis C is an enveloped virus, and the RNA also lacks a proofreading ability after replication, which results in mutations coding for many genotypes within the host. This genetic variability makes it difficult for the host immune system to clear all the HCV infections. As one infection clears, another strain is being produced (Bauman 2012). The HCV antibody detected by ELISA(Wilkinson

A few years ago, Hepatitis C was a scary term for many of us. But, today the medical problem is curable as there are various and advanced ways available. The improvement in the treatment is especially notable because experts have worked harder to obtain this success. Still, there are some significant changes are left and hopefully they will be completed soon. Presently, the HCV treatments get rid of the virus in merely slightly more than half of all sufferers. The medicines also have unnecessary side effects that make it complicated or not possible for some patients to get them. HCV medication online available, but it is not worthy to take them without the concern of the doctor.

About 4.1 million people in Americans have the positive antibody to hepatitis C virus (HCV), and about 75 percent have permeant infection. Additionally, most of the infections happened 20 to 40 years ago, before the finding of HCV. Hepatitis C increased from 7,000 to 13,000 deaths in 2005. Furthermore, HCV develops slowly which increases the risk of severe complications in the infected people. Identification, death, and treatment are predicted to affect 35,000 by 2030. The Center for Disease Control (CDC) used antiviral therapy with PEGylated in clinical trials (Kalichman, Washington, Kegler, Grebler, Kalichman, Cherry, & Eaton, 2015). The CDC recommends a HCV one time test for people born between 1945 and 1965. The objective of this study was to thoroughly evaluate the amount of substance abusers infected with hepatitis C in the United States. Additionally, to observe the treatment of HCV. Currently Medicaid and Medicare repayment standards for sofosbuvir were calculated in all states, including the District of Columbia. Medicaid and Medicare covered the drug based on the following conditions; liver disease stage, HIV, and drug use. Approximately 42 states reimbursed the following criteria up to 74 percent for the drug sofobuvir. About two-thirds of the United States restricted the treatment centered on prescriber type. About 88 percent included drug abuse in their sofosbuvir admissibility measures. Finally, 50 percent required a date of abstinence and 64 percent required

Many people don’t understand how dangerous Hepatitis C is because it is not commonly known about as much as Hepatitis A or B. This disease is however very serious. Although frequently asymptomatic in time the virus can lead to cirrhosis, liver cancer and liver failure. Symptoms of HCV are jaundice (yellowing of the eyes), stomach pain, nausea and fatigue. Treatment options for the disease, if caught early enough is a combination of medications or depending on the degree of damage, a liver transplant. ”For some people, hepatitis C is a short-term illness but for 70%-85% of people who become infected with

In time the virus can lead to cirrhosis, liver cancer and liver failure. Symptoms of HCV are jaundice (yellowing of the eyes), stomach pain, nausea and fatigue. The main problem is that many people don’t have symptoms until they already have some sort of liver damage. Treatment options for HCV include a combination of medications or depending on the degree of damage, a liver transplant. Given that HCV it is a blood disease that is spread through contact with an infected person’s blood, there are many ways to contract this disease. Injection drug users, physical altercations, sexual contact and mother to infant infection are just some of the ways this disease is spread.

Hepatitis C is a prevalent health care problem. According to the Centers of Disease Control and Prevention (CDC, 2016), approximately 2.7-3.9 million of the adult population in the United States is infected with hepatitis C virus (HCV). Some groups of people are at risk for Hepatitis C infection, including current injection drug users, people who received the blood transfusion before 1992, organ recipients from a donor who tested positive for hepatitis C virus, hemodialysis patients, and children born to a hepatitis C mother (CDC, 2016). Hepatitis C causes embarrassment and isolation from the society. Self-esteem and understanding of the family, friend and community will motivate the patient to have a good quality life in society. This

There are a number of individuals who may be suffering from an illness and not even be aware they have an illness. One example of such illness is Hepatitis C (HCV). Hepatitis C is a severe disease of the liver. It is caused by the Hepatitis C virus (Centers for Disease Control and Prevention (CDC), 2015). As a result, Hepatitis C has been termed a silent epidemic (CDC, 2015). This is because a lot of individuals have Hepatitis C and don’t even realize they have the infection (CDC, 2015). As the infection begins to progress over time, it could cause acute issues to the liver (CDC, 2015). Those issues could be things like damage to the liver, the liver could fail to function, cirrhosis, or even cancer of the liver (CDC, 2015). However, screening for Hepatitis C will allow an individual to benefit from treatments that are available, hence eliminating the disease from the body and preventing the liver from undergoing any further damage (CDC, 2015).

Hepatitis C is definitely not a public health crisis that needs emergency intervention in terms of the policy makers being pressured to make a decision urgently. However, thousands of citizens of the United States die on a yearly basis from this contagious disease (CDC, 2014). This makes it a serious public health issue. Hepatitis C is basically a liver disease that is contagious in nature and could be fatal if left untreated. According to the CDC website over 3 million Americans are infected with the disease (HCV), and “approximately 75%–85% of people who become infected with Hepatitis C virus develop chronic infection”. Hepatitis C is most commonly transmitted in the United States through IV drug use (CDC, 2014). Other modes of transmission includes blood transfusion or coming in contact with someone’s blood, accidental needlestick injuries among health care workers (e.g., nurses and phlebotomists), sexual contact (rare) and infants born to mothers who have the disease. These above medical and demographic facts make HCV a serious threat on public health.

Hepatitis C is a prevalent health care problem. According to the Centers of Disease Control and Prevention (CDC, 2016), approximately 2.7-3.9 million of the adult population in the United States is infected with hepatitis C virus (HCV). Some groups of people are at risk for Hepatitis C infection, including current injection drug users, people who received the blood transfusion before 1992, organ recipients from a donor who tested positive for hepatitis C virus, hemodialysis patients, and children born to a hepatitis C mother (CDC, 2016). Hepatitis C causes embarrassment and isolation from the society. Self-esteem and understanding of the

Hepatitis C (HCV) is a blood borne virus that can lead to chronic liver disease and liver failure. In Canada, nearly 250,000 people have an active Hepatitis C infection (Strike, Leonard, Millson, Anstice, Berkeley, & Medd, 2006). People who inject drugs (PWID) are disproportionately represented in this statistic accounting for over 66% of those infected (Strike et al., 2006). Needle sharing among PWID is oft cited as one of the leading causes of HCV transmission (Strike et al. 2006).

Hepatitis C is a disease of the liver that is contagious and over time can cause other harmful problems. Hepatitis C starts off as an acute infection that in many cases can become chronic if not treated right away. Medical professionals work with needles and other sharp objects that come into contact with other people. If they are not careful they can have accidents like needle sticks. Non- medical professionals can be infected by sharing needles for the use of drugs and body art such as tattooing and

Hepatitis is inflammation of the liver. There are currently five known viruses that cause can hepatitis (Microbiology, 10e). The hepatitis C virus (HCV) is transmitted through contact with the blood of an infected person; however, it is now more commonly spread among IV drug users that share needles. Healthcare workers are also at risk for contracting HCV, but with standard precautions, the risk is low. “Prior to 1992, some people acquired the HCV infection from transfusions of blood or blood products. Since 1992, all blood products have been screened for HCV, and cases of HCV due to blood transfusion now are extremely rare. HCV can be passed from mother to unborn child. Approximately 4 out of every 100 infants born to HCV-positive mothers

Hepatitis C has been referred to as a "Silent Epidemic," since it usually progresses slowly over many years. Most people who are infected with hepatitis C are not aware of any noticeable symptoms for as long as one to two decades after they are infected. In fact, by the time symptoms appear, the virus has probably already begun to damage the liver. If the liver is injured and stops functioning, death will always be the outcome (Lieber). Liver failure from chronic hepatitis C is one of the most common causes of liver transplants in the United States.

Hepatitis C is a liver disease that is spread from one person to another by the contact of uninfected blood with that of someone who is infected. After having the disease for a number of years, someone who is infected with Hepatitis C is likely to have liver problems in the future, which could lead to cirrhosis and liver cancer within twenty years of being infected. Over the years, many infectious disease specialists have found treatments that manage the disease, but, in 2013, Gilead Sciences created the medicine by the name of Sofosbuvir (Sovaldi). The difference between Sovaldi and other hepatitis C treatments that have been used over the years is that Sovaldi is the only treatment that cures the disease rather than managing its symptoms in order to decrease the severity like the other treatments do. For this reason many physicians desire to prescribe Sovaldi to suffering patients, but often times cannot do so because the drug is not covered by all State Medicaid policies; therefore, many of these patients are left to suffer with the disease as they do not have the means to find the curing specialty drug. State Medicaid covers many health plans, but some states neglect to cover the specialty drug, Sovaldi; although the addition of coverage for this treatment will have short term negative impacts, the long term effects will overshadow the initial issues.